Cancer Chemotherapy and Biotherapy: Principles and PracticeUpdated to include the newest drugs and those currently in development, this Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised. A companion website includes the fully searchable text and an image bank. |
Contents
Chabner_Chap43 | 773 |
Chabner_Chap21 | 419 |
Chabner_Chap22 | 442 |
Chabner_Chap23 | 459 |
Chabner_Chap24 | 462 |
Chabner_Chap25 | 465 |
Chabner_Chap26 | 495 |
Chabner_Chap27 | 511 |
Chabner_Chap18 | 356 |
Chabner_Chap19 | 392 |
Chabner_Chap20 | 411 |
Chabner_Chap37 | 685 |
Chabner_Chap38 | 708 |
Chabner_Chap39 | 722 |
Chabner_Chap40 | 732 |
Chabner_Chap41 | 746 |
Chabner_Chap28 | 517 |
Chabner_Chap29 | 526 |
Chabner_Chap30 | 547 |
Chabner_Chap08 | 107 |
Chabner_Chap09 | 139 |
Chabner_Chap10 | 171 |
Chabner_Chap11 | 192 |
Chabner_Chap12 | 210 |
Chabner_Chap13 | 216 |
Chabner_Chap14A | 267 |
Chabner_Chap14B | 293 |
Chabner_Chap15 | 310 |
Chabner_Chap16 | 323 |
Chabner_Chap17 | 342 |
Chabner_Chap31 | 577 |
Chabner_Chap32 | 605 |
Chabner_Chap33 | 618 |
Chabner_Chap34 | 632 |
Chabner_Chap01 | 1 |
Chabner_Chap02 | 15 |
Chabner_Chap03 | 28 |
Chabner_Chap04 | 50 |
Chabner_Chap05 | 62 |
Chabner_Chap06 | 80 |
Chabner_Chap07 | 96 |
Chabner_Chap35 | 649 |
Chabner_Chap36 | 674 |
Other editions - View all
Cancer Chemotherapy and Biotherapy: Principles and Practice Bruce A. Chabner,Dan L. Longo Limited preview - 2010 |
Cancer Chemotherapy and Biotherapy: Principles and Practice Bruce A. Chabner No preview available - 2015 |
Common terms and phrases
5-fluorouracil acid acute administration alkylating agents antibody antigen apoptosis ara-C bevacizumab binding Biochem Biol Chem bleomycin bone marrow bortezomib breast cancer cancer cells capecitabine carboplatin carcinoma cell lines cellular chemotherapy cisplatin clearance Clin Cancer Res Clin Oncol clinical trials colorectal cancer combination concentrations cyclophosphamide cytotoxic disease docetaxel dose drug effects EGFR enzyme estramustine excretion folate function gemcitabine gene growth factor half-life hepatic HER2 high-dose histone deacetylase human increased induced infusion inhibition inhibitors interaction intracellular intravenous irinotecan kinase leucovorin leukemia lung cancer lymphoma mAbs malignancies Mechanism of action mediated metabolism metabolites metastatic methotrexate mg/mē microtubule mitotic murine mutations Natl neurotoxicity oral ovarian oxaliplatin paclitaxel pathway patients with advanced pharmacokinetics phase II study plasma potential proteasome protein receptor reductase regimens renal resistance response schedule signaling solid tumors sorafenib survival target taxanes therapeutic therapy tion tissue toxicity trastuzumab treatment tubulin tumor tumor cells versus vinca alkaloids vitro vivo



